Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial.

Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KE, Tveit KS, Lorentzen M, Berset IP, Fevang BT, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G, Henriksen M, Hoie SS, Krogh J, Midtgard IP, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid HU, Strand EK, Skjetne K, Seeberg KA, Torp R, Ystrøm CM, Vold C, Zettel CC, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J, Kvien TK.

J Intern Med. 2019 Feb 14. doi: 10.1111/joim.12880. [Epub ahead of print]

PMID:
30762274
2.

The frequency of intrapartum caesarean section use with the WHO partograph versus Zhang's guideline in the Labour Progression Study (LaPS): a multicentre, cluster-randomised controlled trial.

Bernitz S, Dalbye R, Zhang J, Eggebø TM, Frøslie KF, Olsen IC, Blix E, Øian P.

Lancet. 2019 Jan 26;393(10169):340-348. doi: 10.1016/S0140-6736(18)31991-3. Epub 2018 Dec 20.

PMID:
30581039
3.

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial.

Nordberg LB, Lillegraven S, Aga AB, Sexton J, Olsen IC, Lie E, Berner Hammer H, Uhlig T, van der Heijde D, Kvien TK, Haavardsholm EA.

RMD Open. 2018 Nov 16;4(2):e000752. doi: 10.1136/rmdopen-2018-000752. eCollection 2018.

4.

Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.

Olsen IC, Lie E, Vasilescu R, Wallenstein G, Strengholt S, Kvien TK.

Rheumatology (Oxford). 2018 Nov 30. doi: 10.1093/rheumatology/key338. [Epub ahead of print]

PMID:
30508189
5.

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study.

Norvang V, Sexton J, Kristianslund EK, Olsen IC, Uhlig T, Bakland G, Krøll F, Rødevand E, Wierød A, Kvien TK, Smolen JS, Aletaha D, Haavardsholm EA.

RMD Open. 2018 Oct 26;4(2):e000773. doi: 10.1136/rmdopen-2018-000773. eCollection 2018.

6.

Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: experiences from the nationwide NOCAR project.

Ikdahl E, Rollefstad S, Wibetoe G, Salberg A, Krøll F, Bergsmark K, Kvien TK, Olsen IC, Soldal DM, Bakland G, Lexberg Å, Gjesdal CG, Gulseth C, Haugeberg G, Semb AG.

RMD Open. 2018 Oct 1;4(2):e000737. doi: 10.1136/rmdopen-2018-000737. eCollection 2018.

7.

Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol.

Paulshus Sundlisæter N, Olsen IC, Aga AB, Hammer HB, Uhlig T, van der Heijde D, Kvien TK, Lillegraven S, Haavardsholm EA; ARCTIC study group .

Rheumatology (Oxford). 2018 Nov 1;57(11):2022-2031. doi: 10.1093/rheumatology/key202.

PMID:
30053199
8.

Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases.

Ikdahl E, Wibetoe G, Rollefstad S, Salberg A, Bergsmark K, Kvien TK, Olsen IC, Soldal DM, Bakland G, Lexberg Å, Fevang BTS, Gulseth HC, Haugeberg G, Semb AG.

Int J Cardiol. 2019 Jan 1;274:311-318. doi: 10.1016/j.ijcard.2018.06.111. Epub 2018 Jul 2.

PMID:
30007486
9.

Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes.

Paulshus Sundlisæter N, Aga AB, Olsen IC, Hammer HB, Uhlig T, van der Heijde D, Kvien TK, Lillegraven S, Haavardsholm EA; ARCTIC study group.

Ann Rheum Dis. 2018 Oct;77(10):1421-1425. doi: 10.1136/annrheumdis-2017-212830. Epub 2018 Jun 22.

PMID:
29934373
10.

Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial.

Vik I, Bollestad M, Grude N, Bærheim A, Damsgaard E, Neumark T, Bjerrum L, Cordoba G, Olsen IC, Lindbæk M.

PLoS Med. 2018 May 15;15(5):e1002569. doi: 10.1371/journal.pmed.1002569. eCollection 2018 May.

11.

The Impact of Ultrasound on the Use and Efficacy of Intraarticular Glucocorticoid Injections in Early Rheumatoid Arthritis: Secondary Analyses From a Randomized Trial Examining the Benefit of Ultrasound in a Clinical Tight Control Regimen.

Nordberg LB, Lillegraven S, Aga AB, Sexton J, Lie E, Hammer HB, Olsen IC, Uhlig T, van der Heijde D, Kvien TK, Haavardsholm EA.

Arthritis Rheumatol. 2018 Aug;70(8):1192-1199. doi: 10.1002/art.40494. Epub 2018 Jun 29.

PMID:
29575737
12.

Discrepancies in risk age and relative risk estimations of cardiovascular disease in patients with inflammatory joint diseases.

Wibetoe G, Ikdahl E, Rollefstad S, Olsen IC, Bergsmark K, Kvien TK, Salberg A, Soldal DM, Bakland G, Lexberg Å, Fevang BT, Gulseth HC, Haugeberg G, Semb AG.

Int J Cardiol. 2018 Feb 1;252:201-206. doi: 10.1016/j.ijcard.2017.10.038.

PMID:
29249429
13.

Efficacy of infliximab biosimilars in patients with Crohn's disease - Authors' reply.

Jørgensen KK, Lundin KE, Olsen IC, Kvien TK, Jahnsen J.

Lancet. 2017 Dec 2;390(10111):2436. doi: 10.1016/S0140-6736(17)32463-7. Epub 2017 Dec 1. No abstract available.

PMID:
29208304
14.

Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.

Jonsson MK, Sundlisæter NP, Nordal HH, Hammer HB, Aga AB, Olsen IC, Brokstad KA, van der Heijde D, Kvien TK, Fevang BS, Lillegraven S, Haavardsholm EA.

Ann Rheum Dis. 2017 Dec;76(12):2031-2037. doi: 10.1136/annrheumdis-2017-211695. Epub 2017 Aug 16.

PMID:
28814431
15.

Cardiovascular disease risk profiles in inflammatory joint disease entities.

Wibetoe G, Ikdahl E, Rollefstad S, Olsen IC, Bergsmark K, Kvien TK, Salberg A, Soldal DM, Bakland G, Lexberg Å, Fevang BT, Gulseth HC, Haugeberg G, Semb AG.

Arthritis Res Ther. 2017 Jul 3;19(1):153. doi: 10.1186/s13075-017-1358-1.

16.

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK; NOR-SWITCH study group.

Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11. Erratum in: Lancet. 2017 Jun 10;389(10086):2286.

PMID:
28502609
17.

Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.

Lie E, Lindström U, Zverkova-Sandström T, Olsen IC, Forsblad-d'Elia H, Askling J, Kapetanovic MC, Kristensen LE, Jacobsson LTH.

Ann Rheum Dis. 2017 Sep;76(9):1515-1521. doi: 10.1136/annrheumdis-2016-210931. Epub 2017 Mar 2.

PMID:
28254789
18.

4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State.

Wollmann BM, Syversen SW, Lie E, Gjestad C, Mehus LL, Olsen IC, Molden E.

Clin Transl Sci. 2017 Jan;10(1):42-49. doi: 10.1111/cts.12431. Epub 2016 Nov 5.

19.

Exploring cardiovascular disease risk evaluation in patients with inflammatory joint diseases.

Semb AG, Ikdahl E, Hisdal J, Olsen IC, Rollefstad S.

Int J Cardiol. 2016 Nov 15;223:331-336. doi: 10.1016/j.ijcard.2016.08.129. Epub 2016 Aug 7.

PMID:
27543704
20.

Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial.

Haavardsholm EA, Aga AB, Olsen IC, Lillegraven S, Hammer HB, Uhlig T, Fremstad H, Madland TM, Lexberg ÅS, Haukeland H, Rødevand E, Høili C, Stray H, Noraas A, Hansen IJ, Bakland G, Nordberg LB, van der Heijde D, Kvien TK.

BMJ. 2016 Aug 16;354:i4205. doi: 10.1136/bmj.i4205.

21.

Calcium supplementation and inflammation increase mortality in rheumatoid arthritis: A 15-year cohort study in 609 patients from the Oslo Rheumatoid Arthritis Register.

Provan SA, Olsen IC, Austad C, Haugeberg G, Kvien TK, Uhlig T.

Semin Arthritis Rheum. 2017 Feb;46(4):411-417. doi: 10.1016/j.semarthrit.2016.07.011. Epub 2016 Jul 26.

PMID:
27522465
22.

Sleep disturbance in patients with rheumatoid arthritis is related to fatigue, disease activity, and other patient-reported outcomes.

Austad C, Kvien TK, Olsen IC, Uhlig T.

Scand J Rheumatol. 2017 Mar;46(2):95-103. doi: 10.3109/03009742.2016.1168482. Epub 2016 Jun 20.

PMID:
27319613
23.

Predictive Value of Arterial Stiffness and Subclinical Carotid Atherosclerosis for Cardiovascular Disease in Patients with Rheumatoid Arthritis.

Ikdahl E, Rollefstad S, Wibetoe G, Olsen IC, Berg IJ, Hisdal J, Uhlig T, Haugeberg G, Kvien TK, Provan SA, Semb AG.

J Rheumatol. 2016 Sep;43(9):1622-30. doi: 10.3899/jrheum.160053. Epub 2016 Jun 15.

PMID:
27307523
24.

The association of hypertension with asymptomatic cardiovascular organ damage in rheumatoid arthritis.

Midtbø H, Gerdts E, Kvien TK, Olsen IC, Lønnebakken MT, Davidsen ES, Rollefstad S, Semb AG.

Blood Press. 2016 Oct;25(5):298-304. doi: 10.3109/08037051.2016.1172867. Epub 2016 Apr 28.

PMID:
27123584
25.

Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria.

Nordberg LB, Lillegraven S, Lie E, Aga AB, Olsen IC, Hammer HB, Uhlig T, Jonsson MK, van der Heijde D, Kvien TK, Haavardsholm EA; and the ARCTIC working group.

Ann Rheum Dis. 2017 Feb;76(2):341-345. doi: 10.1136/annrheumdis-2015-208873. Epub 2016 Apr 19.

PMID:
27094444
26.

Sustained Improvement of Arterial Stiffness and Blood Pressure after Long-Term Rosuvastatin Treatment in Patients with Inflammatory Joint Diseases: Results from the RORA-AS Study.

Ikdahl E, Rollefstad S, Hisdal J, Olsen IC, Pedersen TR, Kvien TK, Semb AG.

PLoS One. 2016 Apr 19;11(4):e0153440. doi: 10.1371/journal.pone.0153440. eCollection 2016.

27.

Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.

Uhlig T, Lie E, Norvang V, Lexberg ÅS, Rødevand E, Krøll F, Kalstad S, Olsen IC, Kvien TK.

J Rheumatol. 2016 Apr;43(4):716-23. doi: 10.3899/jrheum.151132. Epub 2016 Feb 15.

PMID:
26879358
28.

Involvement of the multidisciplinary team and outcomes in inpatient rehabilitation among patients with inflammatory rheumatic disease.

Uhlig T, Bjørneboe O, Krøll F, Palm Ø, Olsen IC, Grotle M.

BMC Musculoskelet Disord. 2016 Jan 13;17:18. doi: 10.1186/s12891-016-0870-9.

29.

Effectiveness of an Integrated Multidisciplinary Osteoarthritis Outpatient Program versus Outpatient Clinic as Usual: A Randomized Controlled Trial.

Moe RH, Grotle M, Kjeken I, Olsen IC, Mowinckel P, Haavardsholm EA, Hagen KB, Kvien TK, Uhlig T.

J Rheumatol. 2016 Feb;43(2):411-8. doi: 10.3899/jrheum.150157. Epub 2015 Dec 15.

PMID:
26669917
30.

Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study.

Ikdahl E, Hisdal J, Rollefstad S, Olsen IC, Kvien TK, Pedersen TR, Semb AG.

Arthritis Res Ther. 2015 Oct 8;17:279. doi: 10.1186/s13075-015-0795-y.

31.

First step in the development of an ultrasound joint inflammation score for rheumatoid arthritis using a data-driven approach.

Aga AB, Hammer HB, Olsen IC, Uhlig T, Kvien TK, van der Heijde D, Fremstad H, Madland TM, Lexberg ÅS, Haukeland H, Rødevand E, Høili C, Stray H, Bendvold AN, Soldal DM, Bakland G, Lie E, Haavardsholm EA.

Ann Rheum Dis. 2016 Aug;75(8):1444-51. doi: 10.1136/annrheumdis-2015-207572. Epub 2015 Jun 17.

PMID:
26085490
32.

Performance development in adolescent track and field athletes according to age, sex and sport discipline.

Tønnessen E, Svendsen IS, Olsen IC, Guttormsen A, Haugen T.

PLoS One. 2015 Jun 4;10(6):e0129014. doi: 10.1371/journal.pone.0129014. eCollection 2015.

33.

EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic.

Ikdahl E, Rollefstad S, Olsen IC, Kvien TK, Hansen IJ, Soldal DM, Haugeberg G, Semb AG.

Biomed Res Int. 2015;2015:515280. doi: 10.1155/2015/515280. Epub 2015 Mar 1.

34.

CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up.

Berg IJ, Semb AG, van der Heijde D, Kvien TK, Olsen IC, Dagfinrud H, Provan SA.

Ann Rheum Dis. 2015 Aug;74(8):1562-6. doi: 10.1136/annrheumdis-2014-206773. Epub 2015 Mar 20.

PMID:
25795906
35.

Rosuvastatin-Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study.

Rollefstad S, Ikdahl E, Hisdal J, Olsen IC, Holme I, Hammer HB, Smerud KT, Kitas GD, Pedersen TR, Kvien TK, Semb AG.

Arthritis Rheumatol. 2015 Jul;67(7):1718-28. doi: 10.1002/art.39114.

36.

Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study.

Sveaas SH, Berg IJ, Provan SA, Semb AG, Olsen IC, Ueland T, Aukrust P, Vøllestad N, Hagen KB, Kvien TK, Dagfinrud H.

Scand J Rheumatol. 2015;44(2):118-24. doi: 10.3109/03009742.2014.956142.

PMID:
25756521
37.

Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study.

Berg IJ, van der Heijde D, Dagfinrud H, Seljeflot I, Olsen IC, Kvien TK, Semb AG, Provan SA.

J Rheumatol. 2015 Apr;42(4):645-53. doi: 10.3899/jrheum.141018. Epub 2015 Feb 1.

PMID:
25641897
38.

NOR-DMARD data management: implementation of data capture from electronic health records.

Olsen IC, Haavardsholm EA, Moholt E, Kvien TK, Lie E.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-158-62. Epub 2014 Oct 30.

PMID:
25365108
39.

Efficacy of high intensity exercise on disease activity and cardiovascular risk in active axial spondyloarthritis: a randomized controlled pilot study.

Sveaas SH, Berg IJ, Provan SA, Semb AG, Hagen KB, Vøllestad N, Fongen C, Olsen IC, Michelsen A, Ueland T, Aukrust P, Kvien TK, Dagfinrud H.

PLoS One. 2014 Sep 30;9(9):e108688. doi: 10.1371/journal.pone.0108688. eCollection 2014.

40.

Disease activity and left ventricular structure in patients with rheumatoid arthritis.

Midtbø H, Gerdts E, Kvien TK, Olsen IC, Hirth A, Davidsen ES, Semb AG.

Rheumatology (Oxford). 2015 Mar;54(3):511-9. doi: 10.1093/rheumatology/keu368. Epub 2014 Sep 14.

PMID:
25224414
41.

Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: a cross-sectional study.

Berg IJ, Semb AG, van der Heijde D, Kvien TK, Hisdal J, Olsen IC, Dagfinrud H, Provan SA.

Semin Arthritis Rheum. 2014 Dec;44(3):309-13. doi: 10.1016/j.semarthrit.2014.05.017. Epub 2014 May 20.

PMID:
24968705
42.

A large conditioned pain modulation response is not related to a large blood pressure response: a study in healthy men.

Nilsen KB, Olsen IC, Solem AN, Matre D.

Eur J Pain. 2014 Oct;18(9):1271-9. doi: 10.1002/j.1532-2149.2014.486.x. Epub 2014 Mar 26.

PMID:
24677417
43.

Genetic risk scores and number of autoantibodies in patients with rheumatoid arthritis.

Maehlen MT, Olsen IC, Andreassen BK, Viken MK, Jiang X, Alfredsson L, Källberg H, Brynedal B, Kurreeman F, Daha N, Toes R, Zhernakova A, Gutierrez-Achury J, de Bakker PI, Martin J, Teruel M, Gonzalez-Gay MA, Rodríguez-Rodríguez L, Balsa A, Uhlig T, Kvien TK, Lie BA.

Ann Rheum Dis. 2015 Apr;74(4):762-8. doi: 10.1136/annrheumdis-2013-204173. Epub 2013 Dec 13.

PMID:
24336335
44.

Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: results from a followup MRI study of 254 patients in clinical remission or low disease activity.

Gandjbakhch F, Haavardsholm EA, Conaghan PG, Ejbjerg B, Foltz V, Brown AK, Døhn UM, Lassere M, Freeston JE, Olsen IC, Bøyesen P, Bird P, Fautrel B, Hetland ML, Emery P, Bourgeois P, Hørslev-Petersen K, Kvien TK, McQueen FM, Østergaard M.

J Rheumatol. 2014 Feb;41(2):398-406. doi: 10.3899/jrheum.131088. Epub 2013 Dec 15.

PMID:
24334647
45.

Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.

Aga AB, Lie E, Uhlig T, Olsen IC, Wierød A, Kalstad S, Rødevand E, Mikkelsen K, Kvien TK, Haavardsholm EA.

Ann Rheum Dis. 2015 Feb;74(2):381-8. doi: 10.1136/annrheumdis-2013-204020. Epub 2013 Nov 27.

PMID:
24285493
46.

Health status has improved more in women than in men with rheumatoid arthritis from 1994 to 2009: results from the Oslo rheumatoid arthritis register.

Austad C, Kvien TK, Olsen IC, Uhlig T.

Ann Rheum Dis. 2015 Jan;74(1):148-55. doi: 10.1136/annrheumdis-2013-204014. Epub 2013 Oct 15.

PMID:
24130265
47.

Associations between APOE genotypes and disease susceptibility, joint damage and lipid levels in patients with rheumatoid arthritis.

Maehlen MT, Provan SA, de Rooy DP, van der Helm-van Mil AH, Krabben A, Saxne T, Lindqvist E, Semb AG, Uhlig T, van der Heijde D, Mero IL, Olsen IC, Kvien TK, Lie BA.

PLoS One. 2013 Apr 17;8(4):e60970. doi: 10.1371/journal.pone.0060970. Print 2013.

48.

Carotid plaque characteristics and disease activity in rheumatoid arthritis.

Semb AG, Rollefstad S, Provan SA, Kvien TK, Stranden E, Olsen IC, Hisdal J.

J Rheumatol. 2013 Apr;40(4):359-68. doi: 10.3899/jrheum.120621. Epub 2013 Jan 15.

PMID:
23322468
49.

A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation.

Smerud KT, Dolgos S, Olsen IC, Åsberg A, Sagedal S, Reisæter AV, Midtvedt K, Pfeffer P, Ueland T, Godang K, Bollerslev J, Hartmann A.

Am J Transplant. 2012 Dec;12(12):3316-25. doi: 10.1111/j.1600-6143.2012.04233.x. Epub 2012 Sep 4.

50.

ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.

Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Lilleås F, Pedersen T, Bjørnarå B, Dalene F, Kleveland G, Schepel J, Olsen IC, Myhr KM.

Arch Neurol. 2012 Aug;69(8):1044-51. doi: 10.1001/archneurol.2012.283.

PMID:
22507886

Supplemental Content

Loading ...
Support Center